Skip to main content
Download PDF

Comparison of oral and intravenous tranexamic acid in total hip arthroplasty: a systematic review and meta-analysis

Arthroplasty volume 2, Article number: 9 (2020) Cite this article

Abstract

Background

Total hip arthroplasty is associated with substantial blood loss which can lead to postoperative anemia. The purpose of this systematic review and meta-analysis was to compare efficacy and safety of oral tranexamic acid (TXA) and intravenous TXA.

Methods

PubMed, EMBASE, and Cochrane Library were searched from inception until December 2019. A combined searching strategy of subject words and random words was adopted. Only clinical randomized controlled trials were included. The comparisons were made with regard to total blood loss, hemoglobin drop, transfusion rate, and postoperative thromboembolic complications including deep vein thrombolism (DVT) and pulmonary embolism (PE). The meta-analysis was conducted by using the Review Manager 5.3, and bias evaluation was performed based on the Cochrane Handbook 5.1.0.

Results

In this meta-analysis, five randomized controlled trials were included. The results showed that there were no significant differences between the oral TXA group and intravenous TXA group concerning total blood loss [mean difference (MD) =3.01, 95% confidence interval (95% CI): − 43.90 to 49.92, p = 0.90], hemoglobin drop (MD = 0.05, 95% CI: − 0.10 to 0.20, p = 0.50) and transfusion rate of allogeneic blood [risk ratio (RR) =1.09, 95% CI: 0.46 to 2.62, p = 0.84]. No significant difference was found in the incidence of thromboembolic events (RR = 1.71, 95% CI: 0.71 to 4.16, p = 0.97).

Conclusions

Compared with intravenous TXA, oral TXA is equally able to reduce total blood loss, hemoglobin drop, and transfusion requirement for total hip arthroplasty. It is a lower-cost method that does not increase the incidence of thromboembolic events.

Background

Total hip arthroplasty (THA) has been demonstrated to be an effective surgical alternative for patients with end-stage hip diseases [1]. More than 500,000 THAs are performed each year in the UK and USA [2].

THA is associated with substantial blood loss which can lead to postoperative anemia [3,4,5,6]. Kim et al [4] reported that in the THA procedure, the blood loss ranged between 1000 and 2000 ml, and this increased the requirement of allogeneic blood transfusion. However, allogeneic blood transfusion might increase the risk of adverse effects, such as viral infection, immune response, cardiovascular dysfunction, added cost and even death [7,8,9,10,11,12,13]. Recently, the enhanced recovery after surgery protocol has been improved in THA, and the key to the improvement is the blood management [14,15,16]. A variety of methods have been used to reduce blood loss, including controlled hypotension, regional anaesthesia, autologous blood transfusion, intra-operative blood salvage, and the administration of erythropoietin and antifibrinolytic agents [17, 18].

THA may cause hyperfibrinolysis that may last up to 18 h postoperatively [19]. Lee et al. [18] reported that hyperfibrinolysis may account for 60% of total blood loss. Therefore, attention should be paid to peri-operative application of antifibrinolytics. Antifibrinolytics include Tranexamic acid (TXA), aprotinin and ε-aminocaproic acid, etc.

TXA is a synthetic lysine analog that works by binding to plasminogen and blocking the interaction of plasminogen with fibrin, thereby inhibiting fibrinolysis [20, 21]. This mechanism helps reduce blood loss, but theoretically may also put the patient at an increased risk for thromboembolic events [22]. Recently, multiple studies showed that intravenous TXA during perioperation could effectively reduce blood loss without increasing the risk for thromboembolic events. However, the relevant studies on oral modules are not sufficient, leading to a disagreement over its efficacy and safety.

The purpose of this systemic review and meta-analysis was to verify the efficacy and safety of oral TXA. Our hypothesis was that oral TXA might be as effective and safe as intravenous TXA in patients who undergo THA.

Materials and methods

Search strategy

Two reviewers (Yiming Qi and Yingjuan Li) searched PubMed, EMBASE, and Cochrane Library respectively from inception until December 2019. A combined searching strategy of subject words and random words was adopted. The key words, including “THR”, “Arthroplasty, Replacement, Hip”, “THA”, “total hip replacement”, “total hip arthroplasty” and “tranexamic acid” were used in combination. The concrete searching strategy for PubMed was as follows: (((((((THR) OR “Arthroplasty, Replacement, Hip”[Mesh]) OR THA) OR total hip replacement) OR total hip arthroplasty) AND tranexamic acid) AND oral). We included randomized controlled trials (RCTs) that compared oral TXA with intravenous TXA for reducing blood loss or transfusion in patients who underwent THA. Reference lists of all eligible studies and relevant reviews were manually searched for additional studies.

Eligibility criteria

Inclusion criteria were as follows:

  1. 1)

    Patients: adult patients who underwent THA.

  2. 2)

    Intervention: perioperative application of oral or intravenous TXA.

  3. 3)

    Comparison: comparing oral TXA with intravenous TXA.

  4. 4)

    Outcomes: the outcomes concerning efficacy included total blood loss, hemoglobin drop, and transfusion rate; the rate of thromboembolic complications including deep vein thrombosis and pulmonary embolism was chosen as the outcome concerning safety. Total blood loss was selected as the primary outcome.

  5. 5)

    Type of studies: only clinical RCTs were included.

Exclusion criteria were as follows

  1. 1)

    Patients: underage patients or adult patients who underwent revision THA or bilateral THA.

  2. 2)

    Intervention: topical administration of TXA.

  3. 3)

    Comparison: no comparison was made between oral TXA and intravenous TXA.

  4. 4)

    Outcomes: total blood loss was not included as an outcome.

  5. 5)

    Type of studies: non-RCTs or concrete description unsuitable for data extraction; basic or laboratory RCTs; letters and comments.

Data extraction

Two authors (Yiming Qi and Yingjuan Li) independently used the aforementioned search strategy to select the articles from the databases. The titles and abstracts of the articles were reviewed separately. When there was a doubt, the full-text was retrieved for further scrutiny. The included studies were examined thoroughly and independently by two authors (Yiming Qi and Yingjuan Li), and the key data were extracted. Disagreement was resolved by comparing notes or consulting a senior reviewer. The data extracted included author name, country, publish year, sample size, mean age, number of female patients, TXA intervention, prophylactic use of antithrombotics, transfusion criteria and outcome data.

Quality of included studies

Two reviewers (Yiming Qi and Yingjuan Li) independently assessed the risk of bias of every RCT according to the rules of Cochrane Handbook 5.1.0. We created a ‘risk of bias’ table containing the following 7 items: random sequence generation, allocation concealment, blinding, incomplete outcome data, free of selective reporting and other bias. All the items were described as “low risk of bias,” “unclear risk of bias,” or “high risk of bias.”

Statistical analysis

Meta-analysis was conducted by using the Review Manager 5.3 software pakage (The Cochrane Collaboration, Oxford, UK). For dichotomous data, the risk ratio (RR) with 95% confidence interval (95% CI) was calculated (the transfusion rate and the occurrence of thromboembolic events), and for continuous variables (total blood loss, hemoglobin drop) the mean differences (MDs) were calculated. Statistical heterogeneity was assessed with the p and I2 values using the standard Chi-square test. I2 > 50% or p < 0.1 indicated a significant heterogeneity and a random-effects model was applied for the meta-analysis. Otherwise, a fixed-effects model was used.

Results

Search results

A total of 137 studies were identified from the search of the databases and none of them came from other sources. Eighty-six studies remained after the duplicates were removed. Then, we scanned the titles and the abstracts of the 86 citations according to the inclusion and exclusion criteria. As a consequence, 80 citations were excluded. Next, the six remaining studies were carefully full-text-reviewed. Finally five RCTs [23,24,25,26,27] were included in the meta-analysis (Fig. 1).

Fig. 1
figure1

Preferred reporting items for systematic reviews and meta-analyses

Full size image

Quality of the included studies

Risk of bias in the included studies is shown in Figs. 2 and 3. For every bias item, the risk is presented as the percentage across all included studies, which indicates the proportion of different levels of risk of bias for each item. Among the included studies, three studies were randomized by computer-generated numbers [25,26,27], one by random number technique [24], and the remaining one did not report the method of random sequence generation [23]. Four studies conducted the concealment with sealed, opaque envelope [23,24,25,26]. Double-blinding was reported in all the five included studies [23,24,25,26,27]. In four studies the outcome assessors were blinded [23,24,25,26], and in the remaining one [27], the data analyst was not blinded.

Fig. 2
figure2

Risk of bias graph

Full size image
Fig. 3
figure3

Risk of bias summary

Full size image

General characteristics of included studies

All included studies were RCTs published between 2017 and 2018. Four studies were conducted in China and one in the USA. The sample size of the groups ranged from 40 to 60 and the average age of every group varied between 55 to 67.6 years old. As to transfusion indications, in all the studies, transfusion was given when the level of hemoglobin was < 70 g/L or 70–100 g/L with accompanying symptoms of anemia. For deep vein thrombosis prophylaxis, low molecular weight heparin was used in hospital, and in the four Chinese researches, Rivaroxaban was administered after the patients were discharged. Three studies adopted multiple doses [23, 26, 27], and in the other two studies a single dose was applied to every patient [24, 25] (Table 1).

Table 1 General characteristics of included studies
Full size table

Outcomes for meta-analysis

Total blood loss

Five studies involving 491 patients reported the total blood loss. A fixed-effects model was applied because no significant heterogeneity was found among these studies (p = 0.96, I2=0%). No significant difference was detected in the total blood loss between the two groups (MD = 3.01, 95% CI: − 43.90 to 49.92, p = 0.90, Fig. 4). Funnel plot for total blood loss was employed to evaluate publication bias. The funnel plot shows little asymmetry which suggests little publication bias for the meta-analysis of total blood loss (Fig. 5).

Fig. 4
figure4

Forest plot for total blood loss

Full size image
Fig. 5
figure5

Funnel plot for total blood loss

Full size image

Hemoglobin drop

Five studies involving 491 patients reported the post-operation hemoglobin drop. A fixed-effects model was applied because no significant heterogeneity was found among these studies (p = 0.66, I2=0%). No significant difference was detected in the total blood loss between the two groups (MD = 0.05, 95% CI: − 0.10 to 0.20, p = 0.50, Fig. 6).

Fig. 6
figure6

Forest plot for hemoglobin drop

Full size image

Transfusion rate

Four studies involving 383 patients reported the transfusion rate. A fixed-effects model was applied because no significant heterogeneity was found among these studies (p = 0.62, I2=0%). No significant difference was detected in the transfusion rate between the two groups (RR = 1.09, 95% CI: 0.46 to 2.62, p = 0.84, Fig. 7).

Fig. 7
figure7

Forest plot for transfusion rate

Full size image

Thromboembolic events

Two studies involving 188 patients reported the incidence of thromboembolic events. A fixed-effects model was applied because no significant heterogeneity was found among these studies (p = 0.66, I2=0%). No significant difference was detected in the incidence of thromboembolic events between the two groups (RR = 1.71, 95% CI: 0.71 to 4.16, p = 0.23, Fig. 8).

Fig. 8
figure8

Forest plot for the incidence of thromboembolic events

Full size image

Sensitivity analysis and subgroup analysis

No significant heterogeneity was observed in “total blood loss”, “hemoglobin drop”, “transfusion rate”, and “incidence of thromboembolic events”. We excluded one single study to evaluate the influence of the deleted study to the overall result. As a result, omission of any one single study didn’t significantly alter the results, indicating that the results were statistically stable and reliable. No subgroup analysis was conducted for the heterogeneity was low and the number of included studies was small.

Discussion

Blood loss during and after THA ranged from 700 to 2000 mL, which led to 16 to 37% of the patients requiring transfusions [4, 28, 29]. We found both oral and intravenous TXA yielded similar results in terms of the amount of total blood loss, transfusion rate, and hemoglobin drop. This result is in accordance with a former meta-analysis based on five RCTs about arthroplasties [30]. Evangelista et al [31] reported an elevated risk of deep vein thrombosis and pulmonary embolism after application of TXA. However, several meta-analyses showed TXA might not increase thromboembolic events in patients undergoing THA and the incidence of thromboembolic events was very low [30, 32,33,34,35]. Lucas-Polomeni et al [36] reported drug allergy with anaphylactic shock after intravenous TXA. Klak et al [37] reported that topical TXA carried the theoretical risk of periprosthetic infection caused by needle contamination that might even aggravate sepsis. Therefore, the oral form of TXA is considerably safer. Sabbag et al [38] found that, even for patients with a history of VTE, the risk of recurrent VTE (2%) after contemporary THA and TKA was low, and the rate did not increase with the use of intravenous TXA. Besides, we noticed that the patients included in this meta-analysis underwent THA for end-stage hip diseases, such as osteoarthritis, osteonecrosis of the femoral head and developmental dysplasia of hip. Nonetheless, nowadays more and more geriatric patients are suffering from hip fractures, for some of them it may be better to receive THA [39]. Qi et al [40] demonstrated that intravenous TXA reduced total blood loss and transfusion requirements, but did not increase the incidence of thromboembolic events in patients who suffered from hip fractures and underwent THA .

Although Tranexamic acid was discovered more than 50 years ago, the clinical utilization of tranexamic to reduce blood loss and transfusion requirements became popular in the past decade. It was even not included in the 350 essential medicines by the WHO until 2013 [41]. The optimal route, dosage and time for TXA administration in THA remain controversial. In the pooled studies, a loading dose in combination with a following dose or following doses was adopted in three studies [23, 26, 27], and a single bolus dose was administered in two studies [24, 25]. In the two single-dose studies, the average blood loss were more than 1000ml in intravenous and oral TXA groups, and was more substantial than that in the other three studies. Pilbrant et al [42] reported that the bioavailability of oral TXA was only 34% of the same dose of intravenous TXA. In addition, blood TXA was completely eliminated within 8 h. TXA reached a peak 2 to 3 h after oral administration, and the peak plasma level appeared immediately after intravenous administration. The half-life of equipotential doses for the two forms were similar. A TXA plasma concentration of 5 to 10 mg/L has been shown to effectively inhibit fibrinolysis and is considered therapeutic. For oral TXA, it takes approximately 2 h at a dose of 2 g to reach a therapeutic concentration and the level is maintained for approximately 6 h [42]. Some studies showed that hyperfibrinolysis lasted 18 to 24 h postoperatively [43, 44]. Therefore, repeated application of TXA for another 18 to 24 h could further inhibit fibrinolysis, thereby further reducing blood loss. Some studies showed that multiple boluses of oral or IV TXA postoperatively were effective and safe [22, 45,46,47].

Compared with non-pharmacologic hemostatic agents and even with another pharmacological antifibrinolytic (epsilon-aminocaproic acid), TXA is the most cost-effective medicine to minimize perioperative blood loss in THA [31, 48, 49]. Zhao et al [27] showed that the cost of blood transfusion was much lower with oral TXA (US$ 137 total patients) than with intravenous TXA (US$ 273 total patients) or without application of TXA (US$ 1230 total patients). Cao et al [23] found that, compared with intravenous TXA, oral TXA saved US$ 39 per patient during hospitalization. Wu et al [26] reported that the cost of oral TXA (US$ 88 per patient) was significantly lower than that of intravenous TXA (US$ 463 per patient).

Our met-analysis had several strengths. First, this meta-analysis, comparing oral and intravenous TXA solely in THA, included the latest published RCTs. Second, this meta-analysis was methodologically of high quality since it was conducted in strict accordance with the guidelines of the Cochrane Handbook.

Our study had some limitations. First, only five RCTs were included, and the sample size was small. Second, four out of five studies were conducted in the same setting in China. Third, no subgroup analysis was conducted due to a small number of studies. Larger-sample and high-quality RCTs involving different countries and races are warranted for further verification of the efficacy and safety of oral TXA.

Conclusions

Compared with intravenous TXA, oral TXA is equally capable of reducing total blood loss, hemoglobin drop, and transfusion requirement for THA. It is a lower-cost alternative that does not increase the risk for thromboembolic events.

Availability of data and materials

Please contact the authors for relevant data.

Abbreviations

95% CI:

95% confidence interval

DVT:

Deep vein thrombolism

LMWH:

Low molecular weight heparin

MD:

Mean difference

PE:

Pulmonary embolism

RCT:

Randomized controlled trial

RR:

Risk ratio

THA:

Total hip arthroplasty

TXA:

Tranexamic acid

References

  1. 1.

    Jolback P, Rolfson O, Mohaddes M, Nemes S, Karrholm J, Garellick G, et al. Does surgeon experience affect patient-reported outcomes 1 year after primary total hip arthroplasty? Acta Orthop. 2018;89:265–71.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Pivec R, Johnson AJ, Mears SC, Mont MA. Hip arthroplasty. Lancet. 2012;380:1768–77.

    PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81:2–10.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Kim C, Park SS, Davey JR. Tranexamic acid for the prevention and management of orthopedic surgical hemorrhage: current evidence. J Blood Med. 2015;6:239–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Saleh A, Small T, Chandran PA, Schiltz NK, Klika AK, Barsoum WK. Allogenic blood transfusion following total hip arthroplasty: results from the nationwide inpatient sample, 2000 to 2009. J Bone Joint Surg Am. 2014;96:e155.

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Wong S, Tang H, de Steiger R. Blood management in total hip replacement: an analysis of factors associated with allogenic blood transfusion. ANZ J Surg. 2015;85:461–5.

    PubMed  Article  Google Scholar 

  7. 7.

    Appassakij H, Promwong C, Rujirojindakul P, Wutthanarungsan R, Silpapojakul K. The risk of blood transfusion-associated Chikungunya fever during the 2009 epidemic in Songkhla Province, Thailand. Transfusion. 2014;54:1945–52.

    PubMed  Article  Google Scholar 

  8. 8.

    Bilgili MG, Ercin E, Peker G, Kural C, Basaran SH, Duramaz A, et al. Efficiency and cost analysis of cell saver auto transfusion system in total knee arthroplasty. Balkan Med J. 2014;31:149–53.

    PubMed  Google Scholar 

  9. 9.

    Dan M, Liu D, Martos SM, Beller E. Intra-operative blood salvage in total hip and knee arthroplasty. J Orthop Surg (Hong Kong). 2016;24:204–8.

    CAS  Article  Google Scholar 

  10. 10.

    Huang F, Wu D, Ma G, Yin Z, Wang Q. The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. J Surg Res. 2014;186:318–27.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Izuel RM, Garcia EJ, Gomez-Barrera M, Cuenca EJ, Abad SR, Rabanaque HM. Relationship between allogeneic blood transfusion, iron deficiency and nosocomial infection in patients with hip fracture. Med Clin (Barc). 2008;131:647–52.

  12. 12.

    Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667–74.

    PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Zhang H, Chen J, Chen F, Que W. The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2012;20:1742–52.

    PubMed  Article  PubMed Central  Google Scholar 

  14. 14.

    Klapwijk LC, Mathijssen NM, Van Egmond JC, Verbeek BM, Vehmeijer SB. The first 6 weeks of recovery after primary total hip arthroplasty with fast track. Acta Orthop. 2017;88:140–4.

    PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Malek IA, Royce G, Bhatti SU, Whittaker JP, Phillips SP, Wilson IR, et al. A comparison between the direct anterior and posterior approaches for total hip arthroplasty: the role of an ‘enhanced recovery’ pathway. Bone Joint J. 2016;98-B:754–60.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Stowers MD, Manuopangai L, Hill AG, Gray JR, Coleman B, Munro JT. Enhanced recovery after surgery in elective hip and knee arthroplasty reduces length of hospital stay. ANZ J Surg. 2016;86:475–9.

    PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol. 2009;26:722–9.

    PubMed  Article  Google Scholar 

  18. 18.

    Lee QJ, Chang WY, Wong YC. Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty. J Arthroplast. 2017;32:139–42.

    CAS  Article  Google Scholar 

  19. 19.

    Eriksson BI, Hultman E, Martinell S, Eriksson E, Tengborn L, Risberg B. Regional fibrinolysis following total hip replacement. Thromb Res. 1991;62:441–7.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Aguilera-Roig X, Jordan-Sales M, Natera-Cisneros L, Monllau-Garcia JC, Martinez-Zapata MJ. Tranexamic acid in orthopedic surgery. Rev Esp Cir Ortop Traumatol. 2014;58:52–6.

    CAS  PubMed  Google Scholar 

  21. 21.

    Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57:1005–32.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Alipour M, Tabari M, Keramati M, Zarmehri AM, Makhmalbaf H. Effectiveness of oral tranexamic acid administration on blood loss after knee artroplasty: a randomized clinical trial. Transfus Apher Sci. 2013;49:574–7.

    PubMed  Article  Google Scholar 

  23. 23.

    Cao G, Huang Z, Xie J, Huang Q, Xu B, Zhang S, et al. The effect of oral versus intravenous tranexamic acid in reducing blood loss after primary total hip arthroplasty: a randomized clinical trial. Thromb Res. 2018;164:48–53.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Kayupov E, Fillingham YA, Okroj K, Plummer DR, Moric M, Gerlinger TL, et al. Oral and intravenous Tranexamic acid are equivalent at reducing blood loss following total hip arthroplasty: a randomized controlled trial. J Bone Joint Surg Am. 2017;99:373–8.

    PubMed  Article  Google Scholar 

  25. 25.

    Luo ZY, Wang HY, Wang D, Zhou K, Pei FX, Zhou ZK. Oral vs intravenous vs topical tranexamic acid in primary hip arthroplasty: a prospective, randomized, double-blind, controlled study. J Arthroplasty. 2018;33:786–93.

    PubMed  Article  Google Scholar 

  26. 26.

    Wu Y, Zeng Y, Hu Q, Li M, Bao X, Zhong J, et al. Blood loss and cost-effectiveness of oral vs intravenous tranexamic acid in primary total hip arthroplasty: a randomized clinical trial. Thromb Res. 2018;171:143–8.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Zhao H, Xiang M, Xia Y, Shi X, Pei FX, Kang P. Efficacy of oral tranexamic acid on blood loss in primary total hip arthroplasty using a direct anterior approach: a prospective randomized controlled trial. Int Orthop. 2018;42:2535–42.

    PubMed  Article  Google Scholar 

  28. 28.

    Kim JL, Park JH, Han SB, Cho IY, Jang KM. Allogeneic blood transfusion is a significant risk factor for surgical-site infection following total hip and knee arthroplasty: a meta-analysis. J Arthroplast. 2017;32:320–5.

    Article  Google Scholar 

  29. 29.

    Toy PT, Kaplan EB, McVay PA, Lee SJ, Strauss RG, Stehling LC. Blood loss and replacement in total hip arthroplasty: a multicenter study. The preoperative autologous blood donation study group. Transfusion. 1992;32:63–7.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Li GL, Li YM. Oral tranexamic acid can reduce blood loss after total knee and hip arthroplasty: a meta-analysis. Int J Surg. 2017;46:27–36.

    PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Evangelista PJ, Aversano MW, Koli E, Hutzler L, Inneh I, Bosco J, et al. Effect of tranexamic acid on transfusion rates following total joint arthroplasty: a cost and comparative effectiveness analysis. Orthop Clin North Am. 2017;48:109–15.

    PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Gandhi R, Evans HM, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013;6:184.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Li G, Zhang Y, Teng J. Efficiency and safety of oral tranexamic acid in total joint arthroplasty: a meta-analysis of randomized controlled trial. Int J Surg. 2017;47:148–50.

    PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Luo W, Sun RX, Jiang H, Ma XL. The efficacy and safety of topical administration of tranexamic acid in spine surgery: a meta-analysis. J Orthop Surg Res. 2018;13:96.

    PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Chen S, Wu K, Kong G, Feng W, Deng Z, Wang H. The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis. BMC Musculoskelet Disord. 2016;17:81.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  36. 36.

    Lucas-Polomeni MM, Delaval Y, Menestret P, Delaval P, Ecoffey C. A case of anaphylactic shock with tranexamique acid (Exacyl). Ann Fr Anesth Reanim. 2004;23:607–9.

    PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Klak M, Anakkala N, Wang W, Lange S, Jonsson IM, Tarkowski A, et al. Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis. Scand J Infect Dis. 2010;42:351–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Sabbag OD, Abdel MP, Amundson AW, Larson DR, Pagnano MW. Tranexamic acid was safe in arthroplasty patients with a history of venous thromboembolism: a matched outcome study. J Arthroplast. 2017;32:S246–50.

    Article  Google Scholar 

  39. 39.

    Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407–13.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Qi Y, Wang H, Li Y, Ma B, Xie T, Wang C, et al. The efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis. J Orthop Translat. 2019;19:1–11.

    PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    World Health Organization (WHO) (2017) WHO model list of essential medicines. Available at http://www.who.int/medicines/publications/essentialmedicines/en/.

    Google Scholar 

  42. 42.

    Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20:65–72.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Blanie A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, et al. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res. 2013;131:e6–11.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Sharrock NE, Go G, Harpel PC, Ranawat CS, Sculco TP, Salvati EA. The John Charnley Award. Thrombogenesis during total hip arthroplasty. Clin Orthop Relat Res. 1995;319:16–27.

  45. 45.

    Zohar E, Ellis M, Ifrach N, Stern A, Sapir O, Fredman B. The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement. Anesth Analg. 2004;99:1679–83.

    PubMed  Article  Google Scholar 

  46. 46.

    Xie J, Ma J, Yao H, Yue C, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. J Arthroplast. 2016;31:2458–64.

    Article  Google Scholar 

  47. 47.

    Xie J, Hu Q, Ma J, Huang Q, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial. Bone Joint J. 2017;99-B:1442–9.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Lin ZX, Woolf SK. Safety, efficacy, and cost-effectiveness of tranexamic acid in orthopedic surgery. Orthopedics. 2016;39:119–30.

    PubMed  Article  Google Scholar 

  49. 49.

    Ramkumar DB, Ramkumar N, Tapp SJ, Moschetti WE. Pharmacologic hemostatic agents in total joint arthroplasty-a cost-effectiveness analysis. J Arthroplast. 2018;33:2092–9.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by “Summit of the Six Top Talents” Program of Jiangsu Province (2013-WSW-054); Jiangsu Provincial Medical Talent, The Project of Invigorating Health Care through Science, Technology and Education (ZDRCA2016083); Soft Science Research Projects of Nanjing Science and Technology Commission (2016ZD014); The Six Projects Sponsoring Talent Summits of Jiangsu Province, China (LGY2017099).

Author information

Affiliations

  1. Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu, 210009, PR China

    Yiming Qi, Chen Wang, Hui Chen & Yunfeng Rui

  2. Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu, 210009, PR China

    Yiming Qi, Yingjuan Li, Chen Wang, Hui Chen & Yunfeng Rui

  3. Orthopaedic Trauma Institute, Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu, 210009, PR China

    Yiming Qi, Chen Wang, Hui Chen & Yunfeng Rui

  4. Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu, 210009, PR China

    Yiming Qi, Chen Wang, Hui Chen & Yunfeng Rui

  5. School of Medicine, Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu, 210009, PR China

    Yiming Qi, Chen Wang, Hui Chen & Yunfeng Rui

  6. Department of Geriatrics, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu, 210009, PR China

    Yingjuan Li

Authors
  1. Yiming Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yingjuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yunfeng Rui
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YMQ contributed to the study design, performed all data collection and analysis, and wrote the manuscript. YJL, CW and HC participated in the searching of databases, the selection of the included studies and the data analysis. YFR contributed to the study design, data interpretation, and manuscript revision. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Yunfeng Rui.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qi, Y., Li, Y., Wang, C. et al. Comparison of oral and intravenous tranexamic acid in total hip arthroplasty: a systematic review and meta-analysis. Arthroplasty 2, 9 (2020). https://doi.org/10.1186/s42836-020-00027-7

Download citation

Keywords

  • Tranexamic acid
  • Oral
  • Intravenous
  • Total hip arthroplasty
  • Meta-analysis
  • Blood loss

Arthroplasty

ISSN: 2524-7948

Contact us